Sclerocornea in a patient with van den Ende-Gupta syndrome homozygous for a SCARF2 microdeletion by Migliavacca, Michele P et al.
Sclerocornea in a Patient with Van Den Ende–Gupta Syndrome 
Homozygous for a SCARF2 Microdeletion
Michele P. Migliavacca1, Nara L. M. Sobreira2,*, Graziela P.M. Antonialli1, Mariana M. 
Oliveira3, Maria Isabel S.A. Melaragno3, Ingele Casteels4, Thomy de Ravel5, Decio 
Brunoni1, David Valle2, and Ana Beatriz A. Perez1
1Clinical Genetics, Department of Morphology and Genetics, UNIFESP, São Paulo, Brazil
2Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
3Laboratory of Cytogenetics, Genetics, Department of Morphology and Genetics, UNIFESP, São 
Paulo, Brazil
4Department of Pediatric Ophthalmology, University Hospitals Leuven, Leuven, Belgium
5Centre for Human Genetics, UZ Leuven Gasthuisberg Campus, Leuven, Belgium
Abstract
Van den Ende–Gupta Syndrome (VDEGS) is an autosomal recessive disorder characterized by 
blepharophimosis, distinctive nose, hypoplastic maxilla, and skeletal abnormalities. Using 
homozygosity mapping in four VDEGS patients from three consanguineous families, Anastacio et 
al. [Anastacio et al. (2010); Am J Hum Genet 87:553–559] identified homozygous mutations in 
SCARF2, located at 22q11.2. Bedeschi et al. [2011] described a VDEGS patient with sclerocornea 
and cataracts with compound heterozygosity for the common 22q11.2 microdeletion and a 
hemizygous SCARF2 mutation. Because sclerocornea had been described in DiGeorge-velo-
cardio-facial syndrome but not in VDEGS, they suggested that the ocular abnormalities were 
caused by the 22q11.2 microdeletion. We report on a 23-year-old male who presented with 
bilateral sclerocornea and the VDGEGS phenotype who was subsequently found to be 
homozygous for a 17 bp deletion in exon 4 of SCARF2. The occurrence of bilateral sclerocornea 
in our patient together with that of Bedeschi et al., suggests that the full VDEGS phenotype may 
include sclerocornea resulting from homozygosity or compound heterozygosity for loss of 
function variants in SCARF2.
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INTRODUCTION
Van den Ende–Gupta syndrome (VDEGS) (OMIM 600920) is a rare, autosomal recessive 
disorder characterized by blepharophimosis, a characteristic nose, hypoplastic maxilla with 
or without cleft palate, everted lower lip, prominent ears, arachnodactyly, camptodactyly, 
self-limited congenital joint contractures, and skeletal abnormalities (hooked clavicles, 
gracile ribs, long slender bones of hands and feet, mild bowing of long bones). Growth and 
psychomotor development are normal [Gupta et al., 1995; Phadke et al., 1998; Schweitzer et 
al., 2003; Guerra et al., 2005; Carr et al., 2007; Ali et al., 2010]. To date, at least 28 patients 
in 19 families have been described (12 males and 16 females [Gupta et al., 1995; Phadke et 
al., 1998; Schweitzer et al., 2003; Guerra et al., 2005; Carr et al., 2007; Leal and Silva, 
2009; Ali et al., 2010; Anastasio et al., 2010; Bedeschi et al., 2010; Patel et al., 2013]). The 
inheritance pattern is autosomal recessive with frequent parental consanguinity and 
recurrence of the disorder in sibs of unaffected parents. One exception is a kindred with 
three affected individuals, two brothers, and their half-sister, consistent with autosomal 
dominant inheritance with gonadal mosaicism [Leal and Silva, 2009]. Using homozygosity 
mapping in three consanguineous Qatari families, Anastasio et al. [2010] identified 
homozygous mutations in SCARF2 (OMIM 613619), an 11 exon gene located at 22q11.21, 
in four VDEGS patients.
PATIENT AND METHODS
The propositus, his unaffected parents, sister and brother were submitted to the Baylor–
Hopkins Center for Mendelian Genomics (BHCMG) study through the PhenoDB online 
submission portal [Hamosh et al., 2013] for consideration of whole exome sequencing. 
Local approval for this study was provided by the Johns Hopkins Institutional Review 
Board, and all participants signed the appropriate informed consent form.
The propositus is a 23-year-old male who was born at 37 weeks from a G3P3 27-year-old 
mother and a 35-year-old father, his birth weight was 2,900 g. The first cousin parents were 
healthy and from a small city in rural Brazil. The patient has an unaffected sister and 
brother. The mother denied any illnesses or drug exposure during the pregnancy. At birth, 
the patient was noted to have facial anomalies including widely spaced eyes, bilateral 
corneal opacity, and low set and posterior rotated ears. Slender fingers, bilateral adduction 
of his thumbs, and camptodactyly were also present. At 4 months his length was 62.5 cm 
(between the 3rd and 10th centiles), weight was 4,960 g (<3rd centile) and head 
circumference was 40.5 cm (−2 SD). An ophthalmologic evaluation revealed bilateral 
sclerocornea, nystagmus, and strabismus. At 5 years his weight and height were at the 10th 
centile and his head circumference was at −1 SD. His facial dysmorphism was more 
prominent with a high and broad forehead, widely spaced eyes, short palpebral fissures, 
rethrognathia, underdeveloped ala nasi, low hanging columella, protruding ears, everted 
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lower lip, pectus excavatum, slender fingers, camptodactyly, bilateral adducted thumbs, 
hammertoe, and overlapping toes (Fig. 1). His language development was normal but major 
motor development was delayed: he sat at 8 months and walked at 36 months. At age 5 
years, he had mild motor developmental delay but with normal language and cognitive 
function.
At 21 years of age, he showed improvement of his foot contractures but worsening of thumb 
abduction and progression of thoracic scoliosis. His ophthalmologic evaluation revealed 
poor visual acuity. His sclerocornea had progressed with bilateral opaque corneas. Prosthetic 
ocular lenses were used for aesthetic effect. A skeletal survey showed retrognathia, mild 
thickening of the calvarium, sclerosis of mastoid cells, thoraco and thoraco-lumbar scoliosis, 
gracile ribs, narrow iliac bones, slender long bones, mild bowing of the femurs and fibulae, 
short ulnas bilaterally not articulating with the radii, long metatarsii, bilateral valgus 
deformity of the halluces and osteopenia (Fig. 2). A cardiac ultrasound and brain MRI were 
normal. Chromosome analysis at the 500 band level was normal.
RESULTS
We performed whole exome sequencing on the propositus and his unaffected brother and 
applied a filtering designed to prioritize conserved, rare functional variants (missense, 
nonsense, splice site variants, and indels) that were homozygous or in the case of X-linked 
variants, hemizygous, in the proband but not in his unaffected brother. We identified a single 
true positive variant, a 17 bp deletion in exon 4 of SCARF2 (c.438_454del17; 
p.Trp148Alafs*20) that was homozygous and not found in the unaffected brother (see 
Methods in Supplementary materials). Review of the literature on SCARF2 revealed that 
loss of function mutations had been described in four patients with VDEGS from unrelated 
families [Anastacio et al., 2010]. Aside from sclerocornea, the phenotypic features of our 
patient are entirely consistent with the diagnosis of VDEGS. Next we used PCR and Sanger 
sequencing and showed that Individual II-1 has only the wild type 212 bp product, 
individuals I-1, I-2, and II-2 are heterozygotes with both the 212 bp wild type product and 
the mutant 195 bp product, and the individual II-3 has only the mutant 195 bp product (see 
Methods in Supplementary materials). Whole genome SNP genotyping detected no CNVs 
that met our criteria for pathogenicity. We noticed however two large segments of 
homozygosity of 9.4 Mb (16,055,170–25,464,310 bp) and of 7.8 Mb (29,540,129–
37,409,795 bp) on chromosome 22 (see Methods in Supplementary material).
DISCUSSION
Our results and those published previously by two other groups identify LOF variants in 
SCARF2 as the cause of VDEGS [Anastacio et al., 2010; Bedeschi et al., 2010]. SCARF2 
encodes one of two members of the scavenger receptor type F family [Plüddemann et al., 
2007]. Located at 22q11.21, SCARF2 has 11 exons spanning 13,273 bp and encodes two 
isoforms, the longest of which is an 870 amino acid type one integral membrane protein 
with seven complete and three partial N-terminus, extracellular epidermal growth factor 
(EGF) domains and an ~400 residue Serine and Proline rich cytoplasmic C-terminus with 
multiple Serine and Threonine phosphorylation sites. The SCARF2 protein (also known as 
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SREC-II) participates in homophilic and heterophilic (with SCARF1) interactions via its 
multiple EGF domains and interacts with multiple small molecule ligands including 
acetylated low density lipoprotein (Ac-LDL). Northern blot analysis detected a SCARF2 
transcript of about 3.5 kb in most human tissues examined, with highest expression in eye, 
gastrointestinal tract, muscle, ovary, and stomach [Ishii et al., 2002; http://research-
public.gene.com/Research/genentech/genehubgepis/index.html].
Interestingly, Bedeschi et al. [2010] described a patient with VDEGS and unilateral 
sclerocornea. Molecular analysis of this patient, a product of nonconsanguineous parents, 
showed compound heterozygosity for a de novo 22q11.2 microdeletion corresponding to the 
common DiGeorge/VCFS “3 Mb” deletion which includes SCARF2 and a hemizygous 
SCARF2 donor splice site acceptor mutation in intron 4 (c.854 + 1G>T) on the maternal 
allele. Since the sclerocornea had not been reported in any of the 24 patients with VDEGS 
described previously, but had been observed with a frequency of ~0.5% in patients with 22q.
11 deletion syndrome [Binenbaum et al., 2008], the authors concluded that the sclerocornea 
was a consequence of the 22q11 microdeletion [Bedeschi et al., 2010].
Sclerocornea is a developmental anomaly of the eye in which the normally sharp margin 
separating the opaque sclera from the clear cornea is blurred to a variable extent. In the most 
severe form, sclerocornea totalis, the entire cornea is opaque while in milder forms only a 
segment of the corneal margin is blurred with complete sparing of the central cornea. The 
severe form is inherited in an autosomal recessive manner (OMIM 269400), while milder 
forms may segregate as dominant traits (OMIM 181700). Peters anomaly is another 
developmental defect of the anterior segment in which there is a central corneal leukoma (an 
opaque white spot), absence of the posterior corneal stroma and Descemet’s membrane, and 
a variable degree of iris and lenticular attachments to the central aspect of the posterior 
cornea. Peters anomaly and sclerocornea are diagnoses that are often used to label the 
clinical picture of total congenital corneal opacification (CCO) [Mataftsi et al., 2010]. Many 
genes (FOXE3, CYP1B1, SOX2, PITX2, TFAP2A, FOXC1, EYA1, PITX3, FGFR2, PAX6, 
DCN, KERA, B3GALTL, MAF, RAX, VSX1, SLC4A11) are known to be associated to CCO 
but the molecular basis of sclerocornea is not known [Binenbaum et al., 2008; Mataftsi et 
al., 2010].
Aside from sclerocornea, the phenotype of our patient is quite similar to that of previously 
reported VDEGS patients [Gupta et al., 1995; Phadke et al., 1998; Schweitzer et al., 2003; 
Guerra et al., 2005; Carr et al., 2007; Leal and Silva, 2009; Ali et al., 2010; Anastasio et al., 
2010; Bedeschi et al., 2010; Patel et al., 2013]. The remarkable feature that distinguishes our 
patient is the bilateral sclerocornea. However, our results, together with those of Bedeschi et 
al. [2010] suggest the possible involvement of SCARF2 as the cause of sclerocornea in these 
patients. In which case, the phenotype of VDEGS would be expanded to include 
sclerocornea. Moreover, our results suggest an alternative explanation for the previously 
reported 22q11.2 deletion patients with sclerocornea (1 in a series of 240) [Binenbaum et al., 
2008]. We suggest that in these patients, the 22q11.2 deletion exposes a hemizygous loss of 
function variant in SCARF2 on the remaining homolog. Such a model would predict that 
these patients would also have features of VDEG syndrome. A key variable might be the 
severity of the loss of function in the remaining allele; complete loss of function would 
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result in some combination of the 22q11.2 deletion syndrome and VDEGS phenotypes, 
while a more modest loss of function may only add sclerocornea to the 22q11.2 deletion 
phenotype. Interestingly, Casteels and Devriendt [2005] and Erdoğan et al. [2008] each 
described a case of 22q11.2 deletion with unilateral Peters anomaly. The patient described 
by Erdoğan et al. [2008] was a 4-month-old male with facial dysmorphic findings including 
narrow nose, prominent ears, and arachnodactyly of hands and feet, phenotypic features of 
VDEGS but not of the 22q11.2 deletion syndrome. We suggest that the patient described by 
Erdoğan et al. [2008] like the patient described by Bedeschi et al. [2010] has a hemizygous 
loss of function mutation in the second SCARF2 allele resulting in VDEGS. Unfortunately 
this patient is deceased and a DNA sample for SCARF2 sequencing is not available. 
Moreover, we propose that loss of function of SCARF2 may be responsible for the ocular 
abnormalities in our patient and in the patients described by Erdoğan et al. [2008]. We 
further suggest that the patients with sclerocornea associated with 22q11.2 syndrome may 
have a hemizygous loss of function mutations on their remaining SCARF2 allele resulting in 
sclerocornea. In support of this hypothesis, we did not find mutations in the genes known to 
be responsible for CCO [Mataftsi et al., 2011] in our patient. At the present time, however, 
we cannot rule out the possibility that sclerocornea in our patient is caused by recessive or 
dominant mutations in another gene either not detected in our exome sequencing or not yet 
know to cause sclerocornea.
Finally, knowing that SCARF2 heterodimerizes with SCARF1 [Ishii et al., 2002], we suggest 
that sclerocornea might also result from mutations in SCARF1 (17p13.3). We note that 
Rodrigues et al. [1974] described an individual with sclerocornea and an unbalanced 
translocation involving monosomy of 17p and trisomy of 10q. The phenotype of this patient 
included sclerocornea plus several other features possibly related to the 17p and 10q 
imbalance. Although the breakpoints of the 17p translocation were not defined, it is possible 
that perturbation of SCARF1 accounts for the sclerocornea in the patient described by 
Rodrigues et al. [1974].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIG. 1. 
Twenty-year-old patient with bilateral sclerocornea, short palpebral fissures, 
underdeveloped ala nasi, low hanging columella, everted lower lip (A), brachycephaly, low-
set ears and increased posterior angulation, rethrognathia (B), dolichostenomelia, genus 
varus (C), slender fingers, camptodactyly (D), and bilateral adducted thumbs (E).
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FIG. 2. 
Skeletal survey: Scoliosis, slender ribs (A), slender long bones, short ulnas bilaterally not 
articulated with the radii (B), long metacarpus and phalanges (C), mild bowing of the femurs 
(D) and fibulae (E), and long metatarsii and bilateral valgus deformity of the halluces (F).
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